Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome.

Hawk Kim Je Hwan LeeWon-Sik LeeInho KimJoon Ho MoonChul Won ChoiHo Sup LeeJinny ParkYunsuk ChoiHo-Jin ShinSu-Hee ChoKyoung Ha KimSung-Yong KimYoo-Jin Kimnull null

Published in: British journal of haematology (2019)

Keyphrases

multiple myeloma
newly diagnosed
stem cell transplantation
stem cells
mesenchymal stem cells
high dose
smoking cessation